Winning through sharing

In Kos Pharmaceuticals Inc., Jerini AG found a partner willing to share marketing rights while helping to finance development, something it said other potential partners were unwilling to do. Thus, Jerini last week granted North American sales and marketing rights to its lead product, Icatibant, to KOSP.

KOSP (Cranbury, N.J.) obtained exclusive rights to Icatibant for hereditary angioedema (HAE), asthma and refractory ascites in liver cirrhosis

Read the full 655 word article

User Sign In